FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100815761> ?p ?o ?g. }

• W3100815761 abstract "Background Immuno-STATsTM are novel, modular fusion proteins designed to selectively activate tumor-antigen-specific CD8+ T cells. Human papillomavirus (HPV) associated cancers serve as a model system to assess the safety and efficacy of the Immuno-STAT platform. CUE-101 is comprised of human leukocyte antigen (HLA) complex, HLA A*0201, a peptide epitope derived from the HPV type 16 E7 protein, and 4 molecules of a reduced affinity human interleukin-2 (IL2) designed to bind and activate HPV-specific T cells for eradication of HPV16-driven cancers. In preclinical studies CUE-101 demonstrated selective binding, activation, and expansion of HPV16 E7-specific CD8+ T cells, which translated into anti-tumor activity. 1 Methods CUE-101-01 is a first-in-human (FIH) phase 1 study in patients diagnosed with HPV16+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) refractory to one or more lines of therapy. Trial eligibility includes MHC class I type HLA-A*0201 and a diagnosis of an HPV16+ HNSCC, as assessed by p16 IHC and confirmed by HPV16 mRNA ISH. CUE-101 is administered intravenously over 60 minutes every 21 days. Objectives include determination of safety, pharmacodynamics (PD), pharmacokinetics (PK), recommended phase 2 dose (RP2D), and preliminary anti-tumor activity. The safety results from treated participants will be presented. Results 19 participants have received CUE-101 monotherapy as of August 7, 2020. Doses ranging from 0.06 to 1 mg/kg were determined to be safe and well-tolerated, enabling dose escalation to 2 mg/kg. Preliminary PK data demonstrate dose-dependent increases in drug exposure which are sustained upon repeat dosing, and low inter-subject variability. Preliminary data from systemic blood analyses show early signals of expansion of HPV-16 E711-20-specific CD8+ T cells. Stable disease (SD), as determined by RECIST 1.1, was observed in several participants in these early dose cohorts, with one subject maintaining SD up to 19 weeks. The maximum tolerated dose (MTD) has not yet been reached. As of May 14, 2020 (the development safety update report (DSUR) data-lock date), no dose limiting toxicities and the following adverse events were observed in the first 12 patients treated with CUE-101: fatigue (n=3), decreased appetite (n=1), arthralgia (n=1), muscular weakness (n=1), parasthesia (n=1), bullous pemphigoid (n=1), and infusion-related reactions (n=1). Conclusions CUE-101 is a novel agent that is demonstrating acceptable tolerability, favorable PK, and preliminary PD signals that support selective activation of tumor-specific T cells. Neither the MTD nor the monotherapy RP2D have been established. PD and PK analyses are ongoing as dose escalation continues. Acknowledgements The authors would like to thank all the patients who are participating in this study. The study is sponsored by Cue Biopharma. Trial Registration ClinicalTrials. gov NCT03978689 Ethics Approval This study was approved by Ethics and Institutional Review Boards (IRBs) at all study sites; IRB reference numbers: DF/HCC IRB# 19-374 (Massachusetts General Hospital), HRPO# 201905108 (Washington University School of Medicine), IRB 191714 (Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center), Advarra Pro00037736 (Moffitt Cancer Center), IRB(IRBMED) HUM00165746 (University of Michigan Comprehensive Cancer Center), 2019-087 (Karmanos Cancer Institute), WIRB IRB00112341(Winship Cancer Institute/Emory University), WIRB 2000026098 (Yale Cancer Center), WIRB STUDY00008948 (University of Washington, Seattle ), WIRB 1908869642 (University of Arizona Cancer Center, IRB 20-073 (Memorial Sloan Kettering Cancer Center), 2019-0578 (The University of Texas MD Anderson Cancer Center), IRB 52744 (Stanford University School of Medicine). Reference Quayle SN, Girgis N, Thapa DR, et al. CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies. Clin Cancer Res 2020;26:1953–64." @default.
• W3100815761 created "2020-11-23" @default.
• W3100815761 creator A5000011620 @default.
• W3100815761 creator A5002590653 @default.
• W3100815761 creator A5005651831 @default.
• W3100815761 creator A5008487747 @default.
• W3100815761 creator A5016127308 @default.
• W3100815761 creator A5016975405 @default.
• W3100815761 creator A5022036818 @default.
• W3100815761 creator A5023000705 @default.
• W3100815761 creator A5026698479 @default.
• W3100815761 creator A5034980758 @default.
• W3100815761 creator A5036672833 @default.
• W3100815761 creator A5046801940 @default.
• W3100815761 creator A5050190497 @default.
• W3100815761 creator A5052154004 @default.
• W3100815761 creator A5056445926 @default.
• W3100815761 creator A5056900076 @default.
• W3100815761 creator A5063313488 @default.
• W3100815761 creator A5064319129 @default.
• W3100815761 creator A5073246708 @default.
• W3100815761 creator A5073466449 @default.
• W3100815761 creator A5087503746 @default.
• W3100815761 creator A5087520734 @default.
• W3100815761 date "2020-11-01" @default.
• W3100815761 modified "2023-09-23" @default.
• W3100815761 title "354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer" @default.
• W3100815761 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0354" @default.
• W3100815761 hasPublicationYear "2020" @default.
• W3100815761 type Work @default.
• W3100815761 sameAs 3100815761 @default.
• W3100815761 citedByCount "0" @default.
• W3100815761 crossrefType "journal-article" @default.
• W3100815761 hasAuthorship W3100815761A5000011620 @default.
• W3100815761 hasAuthorship W3100815761A5002590653 @default.
• W3100815761 hasAuthorship W3100815761A5005651831 @default.
• W3100815761 hasAuthorship W3100815761A5008487747 @default.
• W3100815761 hasAuthorship W3100815761A5016127308 @default.
• W3100815761 hasAuthorship W3100815761A5016975405 @default.
• W3100815761 hasAuthorship W3100815761A5022036818 @default.
• W3100815761 hasAuthorship W3100815761A5023000705 @default.
• W3100815761 hasAuthorship W3100815761A5026698479 @default.
• W3100815761 hasAuthorship W3100815761A5034980758 @default.
• W3100815761 hasAuthorship W3100815761A5036672833 @default.
• W3100815761 hasAuthorship W3100815761A5046801940 @default.
• W3100815761 hasAuthorship W3100815761A5050190497 @default.
• W3100815761 hasAuthorship W3100815761A5052154004 @default.
• W3100815761 hasAuthorship W3100815761A5056445926 @default.
• W3100815761 hasAuthorship W3100815761A5056900076 @default.
• W3100815761 hasAuthorship W3100815761A5063313488 @default.
• W3100815761 hasAuthorship W3100815761A5064319129 @default.
• W3100815761 hasAuthorship W3100815761A5073246708 @default.
• W3100815761 hasAuthorship W3100815761A5073466449 @default.
• W3100815761 hasAuthorship W3100815761A5087503746 @default.
• W3100815761 hasAuthorship W3100815761A5087520734 @default.
• W3100815761 hasConcept C111113717 @default.
• W3100815761 hasConcept C112705442 @default.
• W3100815761 hasConcept C121608353 @default.
• W3100815761 hasConcept C126322002 @default.
• W3100815761 hasConcept C143998085 @default.
• W3100815761 hasConcept C147483822 @default.
• W3100815761 hasConcept C167672396 @default.
• W3100815761 hasConcept C188280979 @default.
• W3100815761 hasConcept C203014093 @default.
• W3100815761 hasConcept C2776090121 @default.
• W3100815761 hasConcept C2776530083 @default.
• W3100815761 hasConcept C2776833033 @default.
• W3100815761 hasConcept C502942594 @default.
• W3100815761 hasConcept C71924100 @default.
• W3100815761 hasConcept C8891405 @default.
• W3100815761 hasConceptScore W3100815761C111113717 @default.
• W3100815761 hasConceptScore W3100815761C112705442 @default.
• W3100815761 hasConceptScore W3100815761C121608353 @default.
• W3100815761 hasConceptScore W3100815761C126322002 @default.
• W3100815761 hasConceptScore W3100815761C143998085 @default.
• W3100815761 hasConceptScore W3100815761C147483822 @default.
• W3100815761 hasConceptScore W3100815761C167672396 @default.
• W3100815761 hasConceptScore W3100815761C188280979 @default.
• W3100815761 hasConceptScore W3100815761C203014093 @default.
• W3100815761 hasConceptScore W3100815761C2776090121 @default.
• W3100815761 hasConceptScore W3100815761C2776530083 @default.
• W3100815761 hasConceptScore W3100815761C2776833033 @default.
• W3100815761 hasConceptScore W3100815761C502942594 @default.
• W3100815761 hasConceptScore W3100815761C71924100 @default.
• W3100815761 hasConceptScore W3100815761C8891405 @default.
• W3100815761 hasLocation W31008157611 @default.
• W3100815761 hasOpenAccess W3100815761 @default.
• W3100815761 hasPrimaryLocation W31008157611 @default.
• W3100815761 hasRelatedWork W10138567 @default.
• W3100815761 hasRelatedWork W14333088 @default.
• W3100815761 hasRelatedWork W15265948 @default.
• W3100815761 hasRelatedWork W1816852 @default.
• W3100815761 hasRelatedWork W19315091 @default.
• W3100815761 hasRelatedWork W317545 @default.
• W3100815761 hasRelatedWork W5798067 @default.
• W3100815761 hasRelatedWork W5952723 @default.
• W3100815761 hasRelatedWork W828048 @default.
• W3100815761 hasRelatedWork W8724660 @default.
• W3100815761 isParatext "false" @default.
• W3100815761 isRetracted "false" @default.

• next